πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12336983

Inhibition of crystal growth of roflumilast

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12329751

Topical roflumilast formulation having antifungal properties

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12310956

Topical roflumilast formulation having improved delivery and plasma half-life

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12257242

Inhibition of crystal growth of roflumilast

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12220409

Roflumilast formulations with an improved pharmacokinetic profile

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12144802

Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12042558

Method and formulation for improving roflumilast skin penetration lag time

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12016848

Roflumilast formulations with an improved pharmacokinetic profile

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12011437

Roflumilast formulations with an improved pharmacokinetic profile

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12005052

Topical roflumilast formulation having improved delivery and plasma half-life

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12005051

Topical roflumilast formulation having improved delivery and plasma half life

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11819496

Topical roflumilast formulation having improved delivery and plasma half-life

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11793796

Inhibition of crystal growth of roflumilast

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11707454

Topical roflumilast formulation having antifungal properties

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11534493

Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceut

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11129818

Topical roflumilast formulation having improved delivery and plasma half life

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10940142

Inhibition of crystal growth of roflumilast

Arcutis, Inc. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10172841

Inhibition of crystal growth of roflumilast

Arcutis, Inc. Β· Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10105354

Inhibition of crystal growth of roflumilast

Arcutis, Inc. Β· Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9907788

Inhibition of crystal growth of roflumilast

Arcutis, Inc. Β· Granted Tue Mar 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9895359

Inhibition of crystal growth of roflumilast

Arcutis, Inc. Β· Granted Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9884050

Inhibition of crystal growth of roflumilast

Arcutis, Inc. Β· Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9205044

Aqueous pharmaceutical preparation comprising roflumilast

TAKEDA GMBH Β· Granted Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8663694

Taste masked dosage form containing roflumilast

TAKEDA GMBH Β· Granted Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted